Skip to content

ZayaAI Welcomes Pamela Penman to its Board of Advisors

Share This Post

[Bucharest, 23 February 2024] – ZayaAI, a leader in the development of cutting-edge artificial intelligence solutions, is excited to announce the addition of Pamela Penman to its Board of Advisors. As a consultant, Ms. Penman brings a rich background in early commercialization strategy in the biotech industry, dealing with assets from clinical stage through to launch and beyond. Her insights have informed clinical development plans so that relevant data can be generated to secure a relevant and competitive market position. Her deep understanding of market dynamics, regulatory requirements, drug development timelines, and access requirements has allowed Pamela to create targeted commercialization strategies that drive growth and maximize value for her clients.

With over 30 years of experience in pharma and biotech, Pamela has held positions of increasing responsibility in sales and marketing at TAP Pharmaceutical Products Inc. (USA), Amgen Inc. (USA), and Amgen GmbH (Europe).  Understanding the key industry drivers makes her a valuable asset to the ZayaAI team as they continue to innovate and expand their AI capabilities, especially in areas such as pathology diagnostic and AI treatment prediction models.

Cristian Mogodici, CEO of ZayaAI, expressed enthusiasm about the new appointment, stating, “Having Pamela on our advisory board is a significant milestone for ZayaAI. Her proven industry expertise and insight-driven approach to brand commercialization in pharma and biotech are exactly what we need to steer our strategic direction towards groundbreaking AI achievements.”

Pamela Penman commented on her new role, saying, “I am honored to join ZayaAI and contribute to a company that is at the forefront of AI innovation, with the potential to greatly improve both the diagnosis and treatment models that we use today.  The opportunity to apply my industry knowledge and experience to help shape the future of ZayaAI’s technology is incredibly exciting.”

ZayaAI is committed to leading the charge in the AI sector, transforming how industries operate with its advanced AI solutions. The company is confident that Pamela’s insights and leadership will greatly enhance its mission, driving further innovation and success in their mission to bring more accuracy to diagnostics and the ability to predict the most successful treatments in chronic disease for improved patient outcomes and reduced resource utilization.

About ZayaAI

ZayaAI equips pathologists and researchers in clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based ZayaAI products and services aim to improve the efficiency and precision of pathology diagnosis and pathology image analysis beyond current capabilities, across a variety of fields from oncology to dermato-pathology and more.

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Seeing is believing

Book a free demonstration